Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit - Perrigo ( NYSE:PRGO )
Perrigo restated over $1 billion in financial misstatements from 2015-2017. Shares plunged more than 62% after accounting and earnings disclosures. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →
Are Investors Undervaluing Perrigo ( PRGO ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
International Markets and Perrigo ( PRGO ) : A Deep Dive for Investors
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Perrigo ( PRGO ) Loses 16.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Perrigo ( PRGO ) Q2 EPS Rises 7.5%
Perrigo ( NYSE:PRGO ) , a major supplier of over-the-counter ( OTC ) self-care products across North America and Europe, released its Q2 FY2025 financial results on August 6, 2025. The company posted adjusted earnings per share of $0.57, missing the consensus non-GAAP EPS estimate of $0.59.
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut
PRGO tops Q2 EPS but misses revenue. trims 2025 sales outlook, sending shares down in pre-market.
Perrigo ( PRGO ) Lags Q2 Earnings and Revenue Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of -3.39% and -2.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Perrigo ( PRGO ) Could Surge 36.02%: Read This Before Placing a Bet
The mean of analysts' price targets for Perrigo (PRGO) points to a 36% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Perrigo to Report Q2 Earnings: What's in Store for the Stock?
PRGO eyes Q2 results, which are likely to show sales of $1.08 billion, as investors await updates on its Kairos deal and macro pressures.
Is Perrigo ( PRGO ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts Believe Perrigo ( PRGO ) Could Rally 35.36%: Here's is How to Trade
The mean of analysts' price targets for Perrigo (PRGO) points to a 35.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why Perrigo ( PRGO ) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should Value Investors Buy Perrigo ( PRGO ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro Animal Health Corporation ( PAHC ) Hit a 52 Week High, Can the Run Continue?
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Should Value Investors Buy Perrigo ( PRGO ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Does Perrigo ( PRGO ) Have the Potential to Rally 32.86% as Wall Street Analysts Expect?
The consensus price target hints at a 32.9% upside potential for Perrigo (PRGO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Why Is Perrigo ( PRGO ) Down 3.1% Since Last Earnings Report?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Are Investors Undervaluing Perrigo ( PRGO ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Ardelyx Appoints Mike Kelliher Chief Business Officer and James P. Brady Chief Human Resources Officer - Ardelyx ( NASDAQ:ARDX )
WALTHAM, Mass., June 02, 2025 ( GLOBE NEWSWIRE ) -- Ardelyx, Inc.
Wall Street Analysts Predict a 27.28% Upside in Perrigo ( PRGO ) : Here's What You Should Know
The mean of analysts' price targets for Perrigo (PRGO) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is Perrigo ( PRGO ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Perrigo ( PRGO ) Reliance on International Sales: What Investors Need to Know
Evaluate Perrigo's (PRGO) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Enteral Nutrition Market Size is expected to reach US$ 17.33 Billion by 2031, with CAGR of 7.3% | The Insight Partners
US & Canada, May 09, 2025 ( GLOBE NEWSWIRE ) -- According to a new comprehensive report from The Insight Partners, the enteral nutrition market is witnessing significant growth owing to the rising prevalence of chronic diseases and the aging population across the world.
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
Perrigo ( PRGO ) Q1 Earnings Beat Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 3.59%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Perrigo to Report Q1 Earnings: Is a Beat in Store for the Stock?
PRGO's first-quarter top line is likely to have been impacted by exited businesses and product lines, and unfavorable currency movements.
Prestige Consumer Healthcare ( PBH ) Reports Next Week: Wall Street Expects Earnings Growth
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo ( PRGO ) Earnings Expected to Grow: Should You Buy?
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Trump Tariffs Could Have 'Significant Impact' On Perrigo Earnings, Says JP Morgan - Perrigo ( NYSE:PRGO )
Perrigo Q1 2025 earnings are projected at $0.55/share on $1.09 billion sales; tariff impact dominates the outlook. Tariffs may raise global COGS by low to mid-single digits, mainly hitting oral care and infant formula lines. Feel unsure about the market's next move?
Sanara MedTech ( SMTI ) Stock Jumps 8.1%: Will It Continue to Soar?
Sanara MedTech (SMTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Is ProShares S&P MidCap 400 Dividend Aristocrats ETF ( REGL ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Investing in Perrigo ( PRGO ) ? Don't Miss Assessing Its International Revenue Trends
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 - Perrigo ( NYSE:PRGO )
Perrigo shares surged after issuing 2025 financial targets, with sales growth of 1%-3% and adjusted EPS of $2.90-$3.10. Company outlines strategy to improve cash flow, focusing on stabilizing, streamlining, and strengthening key business areas.
Perrigo's Q4 Earnings Beat Estimates, Revenues Decline Y/Y
PRGO reports mixed Q4 2024 results. The decline in the company's top line is due to the loss of sales stemming from exited businesses and product lines.
Perrigo ( PRGO ) Q4 Earnings Beat Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of 1.09% and 4.77%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Countdown to Perrigo ( PRGO ) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Perrigo (PRGO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
What's in Store for These 5 Biotech Stocks This Earnings Season?
Let's look at five biotech and drug companies, VTRS, PRGO, NVAX, NTLA and IOVA, slated to release their fourth-quarter 2024 results on Feb. 27, 2025.
Strong Segmental Performance to Drive Stryker's Q4 Earnings?
SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More - Eli Lilly ( NYSE:LLY )
According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Perrigo ( PRGO ) Up 5.6% Since Last Earnings Report: Can It Continue?
Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nasal Corticosteroids Market to Reach Over $11.4 Billion by 2034 Amid Rising Chronic Respiratory Disorders | Transparency Market Research, Inc.
Wilmington, Delaware, Transparency Market Research Inc.-, Dec. 02, 2024 ( GLOBE NEWSWIRE ) -- The global nasal corticosteroids market ( marché des corticostéroïdes nasaux ) , valued at US$ 6.6 billion in 2023, is projected to grow at a CAGR of 5.2% from 2024 to 2034, reaching an impressive US$ ...
Perrigo ( PRGO ) International Revenue Performance Explored
Review Perrigo's (PRGO) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
PRGO reports weaker-than-expected third-quarter 2024 results. Though management updates top-line guidance for 2024, it reaffirms the bottom-line outlook.
Perrigo ( PRGO ) Q3 Earnings and Revenues Lag Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of -1.22% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Perrigo to Report Q3 Earnings: Here's What to Expect
PRGO's Q3 top line is expected to have been affected by lower net product sales in the United States and unfavorable currency movements in the quarter.
Analysts Estimate QuidelOrtho ( QDEL ) to Report a Decline in Earnings: What to Look Out for
QuidelOrtho (QDEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Perrigo ( PRGO ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Perrigo (PRGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Key Trends in Infant Clinical Nutrition Industry Propel Toward a US$ 49.47 billion Valuation: Fact.MR Study
Rockville Pike, Oct. 17, 2024 ( GLOBE NEWSWIRE ) -- A newly published study by Fact.MR, a market research and competitive intelligence provider, mentions that revenue from the demand for infant clinical nutrition is approximated to reach a valuation of US$ 27.55 billion in 2024.
Global Oral Care Market is Expected to Develop at a High 6.4% CAGR through 2031 | SkyQuest Technology
Westford, USA, Sept. 17, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Oral Care Market will attain a value of USD 65.54 billion by 2031, with a CAGR of 6.4% over the forecast period ( 2024-2031 ) .
